Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
|Videos|September 22, 2016
Improving Alignment Among Specialty Pharmacy Stakeholders
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses actions that can enhance the relationship between manufacturers, payers, providers and patients in specialty pharmacy.
Advertisement
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses actions that can enhance the relationship between manufacturers, payers, providers and patients in specialty pharmacy.
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
2
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
3
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
4
Understanding Kratom: Pharmacology, Safety, and Regulation
5